CRVO CervoMed
- 24.360
- -0.360-1.46%
CervoMed News
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
CervoMed Q1 EPS $(0.41) Misses $(0.39) Estimate, Sales $2.35M Beat $1.35M Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is a 78.97 percent increase over losses of $(1.95) pe
CervoMed 1Q Loss $2.5M >CRVO
CervoMed 1Q Loss $2.5M >CRVO
Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M
08:01 AM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M
Press Release: CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamap
CervoMed | 10-Q: Quarterly report
CervoMed Updates Stakeholders on Clinical and Financial Status
CervoMed Is Maintained at Buy by Canaccord Genuity
CervoMed Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed with a Buy and raises the price target from $50 to $65.
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
CervoMed Shares Operational and Financial Insights Online
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
CervoMed GAAP EPS of -$0.82 Beats by $1.23, Revenue of $7.14M Beats by $3.09M
CervoMed 2023 Loss $2.2M >CRVO
CervoMed 2023 Loss $2.2M >CRVO
Press Release: CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates - Announced private placement of up to $149.4 million led by RA Capital Management with participati
Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will
CervoMed Shares Rise 20% After Private Placement Pricing
By Chris Wack CervoMed shares rose after the company entered into a definitive securities purchase agreement for a private placement to sell 2.5 million units. The neurological disorder-focused comp
CervoMed Prices $50 Million Equity Sale to Private Investors
CervoMed (CRVO) on Thursday priced a private sale of around 2.5 million units that are each composed of a share of common stock and a pre-funded warrant to purchase another share for $19.745. The priv
Analysis
Price Target
No Data
